SCHEDULE: BlackRock Boosts Stake in Tonix Pharma to 7.8%
Beneficial Ownership Report
BlackRock, Inc. has reported an increased beneficial ownership of 7.8% in Tonix Pharmaceuticals Holding Corp., holding 680,036 common shares as of September 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 680,036 shares of Tonix Pharmaceuticals Holding Corp. common stock.
- This represents 7.8% of the total outstanding common stock of Tonix Pharmaceuticals Holding Corp.
- BlackRock, Inc. holds sole voting power over 665,586 shares and sole dispositive power over 680,036 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- Several BlackRock subsidiaries, including BlackRock Advisors, LLC and BlackRock Fund Advisors, are identified as entities that may beneficially own 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The filing is a factual disclosure of beneficial ownership, which is inherently neutral. While an increased institutional stake can be interpreted positively by the market, the document itself does not convey explicit positive or negative sentiment regarding the issuer's performance or outlook.
Positives
- Increased institutional ownership by a major asset manager like BlackRock, Inc. can signal confidence in the company's long-term prospects.
- BlackRock's certification that the shares are held in the ordinary course of business suggests a passive investment strategy, reducing immediate concerns about activist intervention.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Tonix Pharmaceuticals Holding Corp.'s future performance or BlackRock's future investment intentions beyond the current beneficial ownership disclosure.
Management Comments
- BlackRock, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Industry Context
This filing indicates a significant institutional investment by BlackRock, one of the world's largest asset managers, in a pharmaceutical holding company. Such investments are common as large funds diversify their portfolios across various sectors, including biotechnology and pharmaceuticals, which often present opportunities for growth but also carry inherent risks related to drug development and regulatory approvals.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, designating several individuals to execute ownership or control-person reporting requirements. This new Power of Attorney, effective January 21, 2025, revokes a previous one dated April 30, 2023. | 2025-01-21 | This change streamlines BlackRock's internal compliance and reporting processes for SEC filings, but does not directly impact the corporate governance of Tonix Pharmaceuticals Holding Corp. |
Stakeholder Impact
- Shareholders: Increased institutional ownership may lead to greater market stability and liquidity for Tonix Pharmaceuticals Holding Corp.'s stock. It could also be perceived as a vote of confidence from a major investor.
- Investment Community: The disclosure provides transparency regarding significant ownership stakes, which is crucial for market analysis and investment decisions.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney revoked by BlackRock, Inc. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-09-30 | Date of event which requires the filing of this statement (beneficial ownership calculation date). |
| 2025-10-17 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Keywords
Tonix Pharmaceuticals, BlackRock, Institutional Ownership, SEC Filing, Common Stock, Beneficial Ownership, Pharmaceuticals, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.